Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
NEW ORLEANS, Jan. 29, 2016 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 14, 2016 to file lead plaintiff applications in a securities class action lawsuit against Esperion Therapeutics, Inc. (Nasdaq:ESPR), if they purchased the Company’s securities between August 18, 2015 through September 28, 2015, inclusive (the “Class Period”). This action is pending in the United States District Court for the Eastern District of Michigan.
What You May Do
If you purchased shares of Esperion and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by March 14, 2016.
About the Lawsuit
Esperion and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false statements and omissions include, in part, that: (i) there was no clear path to approval for ETC-1002, a once-daily small molecule designed to lower LDL-cholesterol levels while avoiding the side effects associated with other LDL-cholesterol lowering therapies on the market; (ii) the FDA had encouraged Esperion Therapeutics to initiate a cardiovascular outcomes trial (“CVOT”); and (iii) completion of a CVOT could be necessary prior to approval of ETC-1002.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
